Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.33 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148968 | 0.84 | EGFR (0.39) | PARP1EGFRAPPALKGAK | |
| SCHEMBL18630257 | 0.81 | PARP1 (0.48) | PARP1EGFRMAP4K4LMNAPDGFRB | |
| SCHEMBL30317618 | 0.79 | PARP1 (0.47) | PARP1EGFRMAP4K4LMNAMAPT | |
| SCHEMBL1192531 | 0.79 | PARP1 (0.47) | PARP1EGFRMAP4K4LMNAMAPT | |
| SCHEMBL14548704 | 0.77 | PARP1 (0.42) | PARP1EGFRMAP4K4LMNAMAPT | |
| SCHEMBL29390639 | 0.76 | PDE4A (0.53) | PARP1EGFRMAP4K4LMNACCNC | |
| SCHEMBL28532923 | 0.76 | PARP1 (0.44) | PARP1EGFRMAP4K4LMNAPDGFRB | |
| SCHEMBL6978920 | 0.76 | PARP1 (0.44) | PARP1EGFRMAP4K4LMNAMAPT | |
| SCHEMBL140574 | 0.76 | PDE4A (0.53) | PARP1EGFRMAP4K4LMNACCNC | |
| SCHEMBL5930896 | 0.76 | MAP4K4 (0.56) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102702178-B | Process for the preparation of lapatinib and the salts thereof | ITALIANA SINT SPA | 2015-03-04 | — | — | CN | claimed |
| US-8853396-B2 | Methods for the preparation of lapatinib and the salts thereof | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2014-10-07 | — | — | US | claimed |
| EP-2468745-B1 | Process for the preparation of lapatinib and the salts thereof | ITALIANA SINT SPA (IT) | 2013-04-24 | — | — | EP | claimed |
| US-20120245350-A1 | METHODS FOR THE PREPARATION OF LAPATINIB AND THE SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-09-27 | — | — | US | claimed |
| EP-2468745-A1 | Process for the preparation of lapatinib and the salts thereof | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-06-27 | — | — | EP | claimed |
| EP-4619404-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-06-13 | — | — | US | disclosed |
| WO-2024107711-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-116444445-A | Quinazolinone compound and preparation method thereof | 河北科技大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | ADRM1, BRDT, RBX1 | PARP1 375/4885EGFR 1132/4885MAP4K4 3917/4885 |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | PARP1 355/4885EGFR 118/4885MAP4K4 285/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | PARP1 1082/4885EGFR 4/4885MAP4K4 142/4885 |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | PARP1 1082/4885EGFR 4/4885MAP4K4 142/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | PARP1 3776/4885EGFR 3/4885MAP4K4 57/4885 |
| US-20120245350-A1 | METHODS FOR THE PREPARATION OF LAPATINIB AND THE SALTS THEREOF | ABL1, ERBB2, SRC | PARP1 2105/4885EGFR 6/4885MAP4K4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.